Approved but Not Absolved: The Structural Failures That Allow Unsafe Drugs to Linger on the American Market

When the Food and Drug Administration grants market authorization to a new pharmaceutical compound, the public is understandably inclined to interpret that decision as a declaration of safety. In practice, approval represents something considerably more provisional: a regulatory judgment that a drug's benefits, as understood at a specific moment in time and based on a necessarily limited clinical trial population, outweigh its known risks. The critical phrase is known risks. What emerges over months and years of real-world use — across millions of patients who differ substantially from trial enrollees in age, comorbidity burden, and polypharmacy — is a different and often more complicated picture.

The infrastructure responsible for capturing and acting upon that picture is called pharmacovigilance. In the United States, it is insufficiently resourced, structurally fragmented, and, as a growing body of evidence suggests, inadequate to the task of protecting patients from harms that clinical trials were never designed to detect.

The Limits of Pre-Market Evidence

Clinical trials, by design, are optimized for efficacy signals, not long-term safety surveillance. They typically enroll thousands of participants over periods of months to a few years, excluding populations — pregnant women, elderly patients with multiple chronic conditions, individuals on complex medication regimens — who will constitute a significant share of real-world users. The statistical power required to detect rare adverse events, particularly those with latency periods extending beyond the trial window, simply does not exist within pre-market study designs.

This is not a criticism of the trial process per se. It is a structural reality that obligates robust post-market surveillance as a non-negotiable complement to pre-approval review. The problem is that the US regulatory architecture treats post-market monitoring as an afterthought rather than a continuous, binding obligation.

The FDA's primary tool for collecting voluntary adverse event reports — the MedWatch system — relies heavily on spontaneous submissions from clinicians, patients, and manufacturers. Participation is largely voluntary for healthcare providers, and reporting rates for serious adverse events are estimated to capture fewer than ten percent of actual occurrences. The result is a pharmacovigilance database that is structurally biased toward underrepresentation, particularly for events that are subtle, delayed, or difficult to attribute causally to a specific medication.

Case Patterns: When Warning Signs Go Unheeded

The regulatory history of several drug classes illustrates the consequences of this surveillance deficit with uncomfortable clarity. Rosiglitazone, a diabetes medication sold under the brand name Avandia, accumulated cardiovascular risk signals in post-market data for years before a 2007 meta-analysis synthesizing that evidence prompted regulatory action. Internal FDA analyses had identified the concern earlier; the institutional response was delayed. The drug remained on pharmacy shelves throughout this period, prescribed to patients who were not informed of the emerging cardiac risk profile.

Similarly, the opioid epidemic — while rooted in a complex set of commercial, clinical, and regulatory failures — was in part a pharmacovigilance breakdown. Extended-release opioid formulations entered the market with post-market study commitments that were fulfilled years behind schedule or, in some cases, not at all. The FDA's enforcement mechanisms for post-market study compliance were, and in many respects remain, inadequate.

These are not isolated failures attributable to bad actors alone. They reflect systemic conditions: understaffed review divisions, weak enforcement authority over post-market commitments, and a cultural and economic pressure toward keeping approved drugs accessible rather than revisiting approval decisions on the basis of evolving evidence.

The Tension Between Access and Accountability

A recurring counter-argument from industry stakeholders frames aggressive post-market scrutiny as a threat to drug availability. If the FDA becomes more aggressive in withdrawing or restricting approved medications, the argument runs, manufacturers will face greater uncertainty, investment in novel therapeutics will decline, and patients will ultimately suffer reduced access to innovative treatments.

This framing, while politically effective, conflates two distinct regulatory objectives. Strengthening post-market surveillance does not require a lower threshold for approval; it requires a more serious institutional commitment to monitoring what happens after approval. The two functions can and should be calibrated independently. A regulatory environment that prioritizes rapid market access without ensuring the mechanisms to detect and respond to safety signals is not, in any meaningful sense, protecting patients — it is deferring risk into a surveillance vacuum.

European regulatory frameworks offer instructive contrasts. The European Medicines Agency's pharmacovigilance system incorporates mandatory periodic safety update reports, proactive signal detection through the EudraVigilance database, and formal risk management plans as conditions of market authorization. These mechanisms are not without limitations, but they embed post-market accountability into the approval architecture rather than treating it as supplementary.

Toward a More Robust Surveillance Architecture

Reforming US pharmacovigilance requires action on several interconnected fronts.

Mandatory electronic health record integration represents perhaps the highest-leverage intervention available. The FDA's Sentinel System has demonstrated that passive surveillance using real-world electronic claims and clinical data can detect safety signals far more rapidly than voluntary reporting. Expanding Sentinel's scope, funding, and institutional authority — including the capacity to trigger regulatory action based on its findings — would substantially improve the speed and sensitivity of post-market monitoring.

Enforceable post-market study timelines are equally essential. Current FDA authority to mandate post-market studies under the 2007 FDA Amendments Act is meaningful on paper but undermined by limited enforcement capacity. Congressional appropriations that fund dedicated post-market compliance staff, paired with financial penalties for manufacturers who fail to meet study milestones, would convert existing authority into functional accountability.

Transparent signal communication to clinicians and patients must also be reformed. When the FDA identifies an emerging safety concern that does not yet meet the threshold for withdrawal or black-box labeling, there is currently no standardized mechanism for communicating that uncertainty to prescribers. A structured, publicly accessible signal registry — modeled in part on the EMA's ongoing assessments — would allow clinicians to incorporate regulatory uncertainty into prescribing decisions rather than operating in informational darkness.

Finally, conflict-of-interest protections within advisory committees that evaluate post-market safety data warrant continued attention. While recusal requirements exist, the pool of independent experts with deep pharmacological knowledge and no industry financial relationships is narrow. Structural reforms that expand this pool — including funding for independent academic pharmacovigilance research — would strengthen the integrity of post-market review processes.

Conclusion

The FDA's approval of a pharmaceutical product carries enormous weight in the public imagination, and that weight is not undeserved. But approval is, at best, a provisional certification based on incomplete information. The systems charged with completing that information — with tracking what a drug does in the real world, across the full diversity of patients who use it — are not equal to the task as currently constituted.

Strengthening pharmacovigilance is not an act of regulatory hostility toward the pharmaceutical industry. It is the fulfillment of a basic obligation: that the state's endorsement of a medication's safety remains accurate not just at the moment of approval, but across the full arc of a drug's commercial life. Until that obligation is taken seriously as a matter of institutional design and adequate resourcing, patients will continue to bear risks that the regulatory system was built, in principle, to prevent.